Virtual Sessions:
14-18 June 2027
Credits:
3 ECTS
BIP Type:
Discipline-specific
Fields of Study:
Pharmacy / Medicinal Chemistry / Life Sciences — Organic Chemistry, Pharmaceutical Analysis and Technology, Biology, and Health Sciences
Level of Experience:
Bachelor / Master / PhD
Sending partners:
UNIOVI, HS, TUIASI
Available Places: 18 total
1-5 UNIOVI students
1-5 HS students
3-8 TUIASI students
BIP Coordinator
Prof. Cristina Maccallini (Academic Coordinator)
cristina.maccallini@unich.it
MedChem BIP: Exploring Medicinal Chemistry – A Hands-On Journey for Future Scientists
About the programme
The international course “UdA MedChem — Exploring Medicinal Chemistry: A Hands-On Journey for Future Scientists” is a BIP offered by the Department of Pharmacy of the University “G. d’Annunzio” of Chieti-Pescara, in partnership with the Department of Organic Chemistry of the University of Oviedo, the Department of Biomedicine at the School of Health Sciences of the University of Skövde, and the Faculty of Chemical Engineering and Environmental Protection of the “Gheorghe Asachi” Technical University of Iași.
The face-to-face component, hosted in the Medicinal Chemistry Laboratory (MedChemLab) of UdA, aims to inspire and equip students with practical laboratory experience, critical thinking skills, and a deeper understanding of how chemistry drives drug discovery and the development of new nutraceuticals and cosmeceuticals.
The programme addresses cross-cutting topics of importance for various scientific areas, namely students in Medicinal Chemistry, Organic Chemistry, and Pharmaceutical Analysis and Technology:
- Understanding the reactivity and physical-chemical properties of organic substances and their influence on biological activity
- Pharmaceutical analysis to guarantee quality of drugs; main methods of analysis; mechanisms of action at the molecular level
- Sources, methodologies and strategies for drug discovery and design
- Case studies and problem-based learning consolidating theoretical knowledge
- Laboratory classes demonstrating and consolidating knowledge acquired in theoretical sessions
How you will learn
- Classic lectures (blackboard and PowerPoint/presentation tools)
- Case studies and problem-based learning (PBL)
- Hands-on laboratory classes in MedChemLab
- Study visit to industry or research institution
- Remote e-learning plenary lectures by partner university professors
- International and interdisciplinary teamwork
- Individual study (self-directed, supported by supplementary materials)
Assessment: laboratory work report (25%) + written exam covering all subjects of the theoretical component (75%).
Competences you will develope
- Medicinal chemistry, drug synthesis, pharmaceutical analysis and drug discovery/design
- Development of nutraceuticals and cosmeceuticals — health, well-being and emerging technologies
- Hands-on laboratory skills and practical scientific experimentation
- Critical thinking and problem-based learning in interdisciplinary teams
- Internationalisation and intercultural collaboration across partner institutions
- Research collaboration and innovation in life sciences
- Alignment with the INGENIUM “Health, Well-Being, and Emerging Technologies” pathway
Learning Outcomes
After successful completion of the BIP, students will be able to:
- LO1. Understand the behaviour (reactivity) of organic substances and apply this knowledge to medicinal chemistry, including drug synthesis, pharmaceutical analysis, drug discovery and design, and the development of nutraceuticals and cosmeceuticals
- LO2. Analyse the reactivity and physical-chemical properties of organic substances and their influence on biological activity, and explain the mechanisms of action of drugs at the molecular level
- LO3. Apply pharmaceutical analysis methods to guarantee drug quality and describe the main sources, methodologies and strategies used for drug discovery and design
- LO4. Carry out laboratory work in medicinal chemistry, demonstrating and consolidating the theoretical knowledge acquired during the course
- LO5. Collaborate effectively in international and interdisciplinary teams and demonstrate intercultural competence in a scientific context
BIP's Programme
Virtual component (online activities)
Period: 14-18 June 2027
Schedule / Contents:
- Remote lectures delivered by professors of the participating Foreign Universities (6 hours of remote contact — plenaries of 1 hour each)
- Topics covered: complementary perspectives from partner institutions on medicinal chemistry, pharmaceutical sciences and health sciences
Physical component (on-site at TUIASI)
Period: 7-11 June 2027
- Classroom activity (11 hours of contact): lectures on organic reactivity, medicinal chemistry, drug synthesis, pharmaceutical analysis, drug discovery and design, nutraceuticals and cosmeceuticals
- Laboratory practice (6 hours of contact): hands-on work in the Medicinal Chemistry Laboratory (MedChemLab) — experiments demonstrating and consolidating theoretical knowledge
- Study visit (8 hours of contact): visit to a relevant industry or research institution
Duration: 5 days — 25 hours of face-to-face contact
Application requirements
To apply for this BIP you must:
- Be enrolled at one of the INGENIUM partner universities at the time of the programme.
- Apply through your home (sending) institution.
- Have a sufficient level of English (typically B2 or equivalent).
- Be available to participate in both the virtual and physical components of the BIP.
- Meet any specific academic or eligibility requirements indicated for this programme.
How to apply
Applications for this BIP are managed by each INGENIUM partner university.
To apply, please select your home university from the list below and follow the application process indicated on their page. Each institution has its own application platform and procedure.
Related Events
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Education and Culture Executive Agency (EACEA). Neither the European Union nor the granting authority can be held responsible for them.
